Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2587-2593

  Pisters, Louis L ^a   Pettaway, Curtis A ^a   Troncoso, Patricia ^a   McDonnell, Timothy J ^a   Stephens, L Clifton ^a   Wood, Christopher G ^a   Do, Kim Anh ^a   Brisbay, Shawn M ^a   Wang, Xuemei ^a   Hossan, Elizabeth A ^a   Evans, Robert B ^a   Soto, Cindy ^a   Jacobson, Marc G ^a   Parker, Karen ^c   Merritt, James A ^c   Steiner, Mitchell S ^b   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Introgen Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG SCREENING; ECHOGRAPHY; EXPERIMENT; FEVER; FOLLOW UP; GENE EXPRESSION; GENE THERAPY; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION; MALE; NICK END LABELING; PAIN; PERINEUM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN TRANSPORT; SCORING SYSTEM; TIME; TRANSGENE; TREATMENT FAILURE;

ADENOVIRIDAE; AGED; APOPTOSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA FRAGMENTATION; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TIME FACTORS; TRANSGENES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11144356608     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0388     Document Type: Article

References (33)

1. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
2. Hansen R, Oren M. p53: from inductive signal to cellular effect. Curr Opin Genet Dev 1997;7:46-51.
3. Stapleton AM, Timme TL, Gousse AE, et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3:1389-97.
4. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511-6.
5. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158:131-7.
6. Scherr DS, Vaughan ED Jr, Wei J, et al. bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999;162:12-6.
7. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-65.
8. Hall MC, Navone NM, Troncoso P, et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995;45:470-5.
9. Visakorpi T, Kallioniemi OP, Keikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
10. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-21.
11. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
12. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer. J Urol 1997;157:569-74.
13. Navone NM, Labate ME, Troncoso P, et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999;161:304-8.
14. rd Edition. Philadelphia, PA: Lippincott-Raven, 1996. p. 2146-71.
15. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576-80.
16. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
17. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994;54:3662-7.
18. Schumacher G, Bruckheimer EM, Beham AW, et al. Molecular determinants of cell death induction following adenoviral-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer 2001;91:159-66.
19. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995;55:4210-3.
20. Ko SC, Gotoh A, Thalmann GN, et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 1996;7:1683-91.
21. Eastman JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5.
22. Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino JJ. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997;4:129-38.
23. Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Christiano RJ. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996;16:3415-22.
24. Cowen D, Salem N, Ashoori F, et al. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Can Res 2000;6:4402-8.
25. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
26. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Christiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-71.
27. Zhang WW, Fang X, Branch CD, Mazur W, French BA, Roth JA. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 1993;15:868-72.
28. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147-59.
29. Buckheimer EM, Brisbay S, Johnson DJ, Gingrich J, Greenberg N, McDonnell TJ. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 2000;19:5251-8.
30. Dai Y, Schwarz EM, Gu D, Zhang W, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92:1401-5.
31. Clayman GL, El-Nagger AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-32.
32. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-71.
33. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000;18:1050-7.